Publications

5674 Results

United States Intergroup E1609 - A Phase III Randomized Study of Adjuvant Ipilimumab (3 or 10 mg/kg) versus High-Dose Interferon-a2b for Resected High-Risk Melanoma

Authors
A Tarhini;S Lee;F Hodi;U Rao;GI Cohen;O Hamid;L Hutchins;J Sosman;H Kluger;V Sondak;H Koon;DP Lawrence;K Kendra;DR Minor;C Lee;M Albertini;L Flaherty;T Petrella;JM Kirkwood
Journal / Conference
J Clin Oncol 37(suppl; abstr 9504); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), oral
Year
2019
Research Committee(s)
Melanoma
Study Number(s)
CTSU/E1609

Randomized, DoubleBlind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastasectomy: A Trial of the ECOG-ACRIN Cancer Research Group (E2810)

Authors
LJ Appleman;M Puligandla;SK Pal;W Harris;N Agarwal;B Addis Costello;CW Ryan;M Pins;JE Kolesar;DA Vaena;RA Parikh;M Hashmi;JP Dutcher;RS DiPaola;N Haas;M Carducci
Journal / Conference
J Clin Oncol 37(suppl; abstr 4502); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), oral
Year
2019
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/E2810

HSD3B1 and Overall Survival (OS) in Men with Low-Volume (LV) Metastatic Prostate Cancer (PCa) Treated with Androgen Deprivation Therapy (ADT) or Chemohormonal Therapy in the CHAARTED Randomized Trial

Authors
J Hearn;C Sweeney;N Almassi;C Reichard;C Reddy;B Hobbs;DF Jarrard;Y-H Chen;R Dreicer;JA Garcia;M Carducci;R DiPaola;N Sharifi
Journal / Conference
J Clin Oncol 37(suppl; abstr 5020); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), poster discussion
Year
2019
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/E3805

Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx

Authors
J Sparano;RJ Gray;D Makower;T Lively;T Saphner;M Keane;HL Gomez;PS Reddy;T Goggins;I Mayer;D Toppmeyer;A Brufsky;M Goetz;D Hayes;C Dees;K Pritchard;CE Geyer;JA Olson;K Albain;G Sledge
Journal / Conference
J Clin Oncol 37(suppl; abstr 503); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), oral
Year
2019
Research Committee(s)
Breast

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOGACRIN 8143)

Authors
L Harshman;M Puligandla;N Haas;M Allaf;CD Drake;DF McDermott;S Signoretti;D Cella;RT Gupta;B Shuch;T Choueiri;PN Lara;A Kapoor;D Heng;M Jewett;V Masters;M Michaelson;B Leibovich;D Maskens;M Carducci
Journal / Conference
J Clin Oncol 37(suppl; abstr TPS4597); ASCO (5/31-6/4/19, Chicago IL) TIPS, poster session
Year
2019
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/EA8143

E3A06: Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

Authors
S Lonial;S Jacobus;M Weiss;S Kumar;RZ Orlowski;J Kaufman;A Yacoub;F Buadi;T O'Brien;J Matous;D Anderson;R Emmons;M Dhodapkar;L Wagner;S Rajkumar
Journal / Conference
J Clin Oncol 37(suppl; abstr 8001); American Society of Clinical Oncology (5/31 - 6/4/19, Chicago IL), oral
Year
2019
Research Committee(s)
Myeloma
Study Number(s)
CTSU/E3A06

Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study

Authors
V Larsen;W Barlow;JJ Yang;Q Zhu;S Liu;M Kwan;I Ergas;J Roh;L Hutchins;S Kadlubar;K Albain;J Rae;I-T Yeh;P Ravdin;S Martino;A Lyss;CK Osborne;G Hortobagyi;L Kushi;D Hayes;C Ambrosone;S Yao
Journal / Conference
Clinical Breast Cancer Aug;19(4):225-235; Mar 6 [Epub ahead of print]
Year
2019
Research Committee(s)
Breast
PMID
PMID30928413
PMC
PMC6667288
Study Number(s)
SWOG-8897

Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer

Authors
B Guercio;S Zhang;A Venook;F-S Ou;D Niedzwiecki;H-J Lenz;F Innocenti;M Mahoney;B O'Neil;JE Shaw;B Polite;H Hochster;JN Atkins;RM Goldberg;RJ Mayer;CD Blanke;CS Fuchs;JA Meyerhardt
Journal / Conference
American Association for Cancer Research (March 29-Apr 3, 2019 Atlanta, Georgia), poster
Year
2019
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

Authors
C Langer;M Redman;J Wade;C Aggarwal;J Bradley;J Crawford;P Stella;MH Knapp;J Miao;K Minichiello;RS Herbst;K Kelly;DR Gandara;V Papadimitrakopoulou
Journal / Conference
Journal of Thoracic Oncology Oct;14(10):1839-1846; May 31. pii: S1556-0864(19)30414-9. doi: 10.1016/j.jtho.2019.05.029. [Epub ahead of print]
Year
2019
Research Committee(s)
Lung
PMID
PMID31158500
PMC
PMC7017958
Study Number(s)
S1400B

Brief Report: SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

Authors
C Aggarwal;M Redman;PN Lara;H Borghaei;P Hoffman;J Bradley;A Newman;M Feldman;K Minichiello;J Miao;P Mack;V Papadimitrakopoulou;RS Herbst;K Kelly;D Gandara
Journal / Conference
Journal of Thoracic Oncology Oct;14(10):1847-1852; Jun 10. pii: S1556-0864(19)30462-9. doi: 10.1016/j.jtho.2019.05.041. [Epub ahead of print]
Year
2019
Research Committee(s)
Lung
PMID
PMID31195180
PMC
PMC6901020
Study Number(s)
S1400D